A new vaccination campaign against Covid-19 will begin from mid-April in France. Here are the people who are invited.
- A new vaccination campaign against Covid-19 will begin in mid-April in France.
- In a recent notice, HAS indicated the people concerned.
- The vaccines for the spring campaign will be first line that of Pfizer/BioNTech with messenger RNA targeting the Omicron XBB.1.5 variant or second line that of Novavax with recombinant protein.
“A new vaccination campaign against Covid-19 will be proposed in the spring, in accordance with the opinion of the High Authority of Health (HAS)”, said Grégory Emery, Director General of Health, at a press conference. The goal is always to “protect the most vulnerable likely to develop serious forms of the disease”, he added.
Covid-19: the list of people affected by the new vaccination campaign
Concretely, the vaccination campaign will begin in mid-April in France. In a recent review, the HAS indicated more precisely the people concerned, namely:
– French people aged 65 and over;
– infants from 6 months;
– children, adolescents and adults with comorbidities who have a higher risk of severe disease;
– immunocompromised people;
– individuals living in close proximity to or in regular contact with immunocompromised or vulnerable citizens, including professionals in the health and medico-social sectors.
On the other hand, based on the data currently available, the HAS no longer recommends primary vaccination against Covid-19 in the general population. The health agency, however, insists “on the importance of allowing any person who expresses the request to benefit from full coverage of their vaccination against Covid-19”. Nor does it exclude the possibility of “set up a broader vaccination campaign if the epidemiological situation justifies it”.
New vaccination campaign against Covid-19: what products will be injected?
“The vaccines for the spring campaign will be first line that of Pfizer/BioNTech with messenger RNA targeting the Omicron XBB.1.5 variant or second line that of Novavax with recombinant protein” also indicate France Info and AFP.
Currently in France, the number of procedures for suspected Covid-19 and the corresponding share among all SOS Médecins procedures are decreasing in all age groups. “The share of suspected SARS-CoV-2 is highest among those aged 65 or over and among those aged 15-64,” complete Public Health France.
Appearing four years ago, Covid-19 is an infectious disease caused by the SARS-CoV-2 virus.
Most infected people experience mild to moderate respiratory illness and recover without needing special treatment. However, some become seriously ill and require extensive medical care.
